Sutro Biopharma, Inc. (STRO)
STRO Stock Price Chart
Explore Sutro Biopharma, Inc. interactive price chart. Choose custom timeframes to analyze STRO price movements and trends.
STRO Company Profile
Discover essential business fundamentals and corporate details for Sutro Biopharma, Inc. (STRO) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
27 Sept 2018
Employees
269.00
Website
https://www.sutrobio.comCEO
Jane Chung
Description
Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of innovative therapeutic products. Its primary objective is to create protein-based treatments for challenging conditions like cancer and autoimmune disorders. The company achieves this through its proprietary XpressCF+ platform, a unique technology that integrates cell-free protein synthesis with precise, site-specific drug conjugation. Currently, Sutro's pipeline features two lead antibody-drug conjugate (ADC) candidates, both undergoing Phase 1 clinical evaluation. STRO-001 targets the CD74 protein, designed for individuals with multiple myeloma and non-Hodgkin lymphoma. The second candidate, STRO-002, is engineered to bind to folate receptor-alpha, intended for the treatment of ovarian and endometrial cancers. Strategic alliances are also a key part of its strategy, including collaborations and licensing agreements. A partnership with Merck aims to advance research programs involving cytokine derivatives for both oncological and autoimmune applications. Additionally, an agreement with Celgene Corporation focuses on identifying and developing bispecific antibodies and/or ADCs specifically within the immuno-oncology domain. Founded in 2003, the company initially operated under the name Fundamental Applied Biology, Inc. Its corporate headquarters are located in South San Francisco, California.
STRO Financial Timeline
Browse a chronological timeline of Sutro Biopharma, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$2.22, while revenue estimate is $11.78m.
Earnings released on 14 May 2026
EPS came in at -$2.94 falling short of the estimated -$2.32 by -26.72%, while revenue for the quarter reached $14.52m , beating expectations by +63.32%.
Earnings released on 23 Mar 2026
EPS came in at -$5.29 surpassing the estimated -$8.16 by +35.19%, while revenue for the quarter reached $11.65m , beating expectations by +25.82%.
Stock split effective on 3 Dec 2025
Shares were split 1 : 10 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 6 Nov 2025
EPS came in at -$6.70 falling short of the estimated -$4.20 by -59.52%, while revenue for the quarter reached $9.69m , missing expectations by -4.44%.
Earnings released on 7 Aug 2025
EPS came in at -$0.14 surpassing the estimated -$0.39 by +64.10%, while revenue for the quarter reached $63.75m , beating expectations by +616.57%.
Earnings released on 8 May 2025
EPS came in at -$0.91 falling short of the estimated -$0.63 by -44.44%, while revenue for the quarter reached $17.40m , beating expectations by +15.99%.
Earnings released on 13 Mar 2025
EPS came in at -$0.89 falling short of the estimated -$0.86 by -3.49%, while revenue for the quarter reached $14.81m , beating expectations by +21.84%.
Earnings released on 13 Nov 2024
EPS came in at -$0.59 surpassing the estimated -$0.74 by +20.27%, while revenue for the quarter reached $8.52m , missing expectations by -30.06%.
Earnings released on 13 Aug 2024
EPS came in at -$0.59 surpassing the estimated -$0.76 by +22.37%, while revenue for the quarter reached $25.71m , beating expectations by +22.29%.
Earnings released on 13 May 2024
EPS came in at -$0.95 falling short of the estimated -$0.92 by -3.26%, while revenue for the quarter reached $13.01m , beating expectations by +9.13%.
Earnings released on 25 Mar 2024
EPS came in at $0.42 surpassing the estimated -$0.82 by +151.22%, while revenue for the quarter reached $113.72m , beating expectations by +862.92%.
Earnings released on 13 Nov 2023
EPS came in at -$0.81 falling short of the estimated -$0.76 by -6.58%, while revenue for the quarter reached $16.92m , beating expectations by +43.30%.
Earnings released on 10 Aug 2023
EPS came in at -$0.64 surpassing the estimated -$0.73 by +12.33%, while revenue for the quarter reached $10.41m , missing expectations by -17.10%.
Earnings released on 15 May 2023
EPS came in at -$0.76 surpassing the estimated -$0.83 by +8.43%, while revenue for the quarter reached $12.67m , beating expectations by +4.47%.
Earnings released on 30 Mar 2023
EPS came in at -$0.61 surpassing the estimated -$0.64 by +4.69%, while revenue for the quarter reached $8.63m , missing expectations by -22.58%.
Earnings released on 8 Nov 2022
EPS came in at -$0.37 falling short of the estimated -$0.15 by -146.67%, while revenue for the quarter reached $25.15m , missing expectations by -29.59%.
Earnings released on 8 Aug 2022
EPS came in at -$0.55 surpassing the estimated -$0.74 by +25.68%, while revenue for the quarter reached $28.10m , beating expectations by +75.54%.
Earnings released on 9 May 2022
EPS came in at -$0.84 falling short of the estimated -$0.79 by -6.33%, while revenue for the quarter reached $5.90m , missing expectations by -43.62%.
Earnings released on 28 Feb 2022
EPS came in at -$0.83 falling short of the estimated -$0.67 by -23.88%, while revenue for the quarter reached $10.65m , missing expectations by -9.81%.
Earnings released on 10 Nov 2021
EPS came in at -$0.67 matching the estimated -$0.67, while revenue for the quarter reached $8.52m , meeting expectations.
Earnings released on 9 Aug 2021
EPS came in at -$0.13 surpassing the estimated -$0.42 by +69.05%, while revenue for the quarter reached $28.05m , meeting expectations.
STRO Stock Performance
Access detailed STRO performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
